Deciparticles for cancer therapeutics
Deciparticles, ultra-small particles composed of amphiphilic compounds and taxane drugs, address the limitations of conventional nanoparticles by enhancing stability and cellular uptake, leading to improved anti-tumor efficacy.
WO2026147892A1PCT designated stage Publication Date: 2026-07-09SAPU NANO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- SAPU NANO LTD
- Filing Date
- 2025-12-29
- Publication Date
- 2026-07-09
AI Technical Summary
Technical Problem
Conventional drug delivery nanoparticles are prone to early removal from circulation and have slow uptake by target cells, limiting their therapeutic efficacy.
Method used
Development of deciparticles, which are ultra-small particles (5-35 nm) composed of amphiphilic compounds with taxane drugs, providing enhanced stability and cellular uptake through controlled size and molecular interactions.
Benefits of technology
Deciparticles exhibit improved anti-tumor potency, stability, and reduced immunogenicity, allowing for increased drug delivery and cellular penetration, surpassing conventional nanoparticle therapies.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure US2025061494_09072026_PF_FP_ABST
Abstract
This invention relates to compositions, and uses and methods thereof, with therapeutic deciparticles. Described herein are deciparticle (nanoparticle) compositions composed of an amphiphilic compound complexed with an auxiliary compound such as a biologically active molecule. Deciparticles of this invention are active drugs having potency for anti-tumor effects. This invention is also directed to amphiphilic compounds useful for making deciparticle complexes.
Need to check novelty before this filing date? Find Prior Art